Blueprint Medicines Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Revenue	9.57	2.16	2.36	2.7
Revenue Growth (YoY)	304.99%	-8.59%	-12.44%	-
Cost of Revenue	2.37	2.11	0.96	1.01
Gross Profit	7.21	0.05	1.4	1.69
Selling, General & Admin	7.32	7.07	6.3	5.22
Research & Development	18.95	17.94	15.2	5.58
Other Operating Expenses	0.33	0.29	0.23	0.09
Operating Expenses	27.47	26.29	23.03	11.98
Operating Income	-20.26	-26.23	-21.63	-10.28
Interest Expense	-15.42	-8.02	-5.64	-4.09
Interest & Investment Income	0.09	0.25	0.28	0.05
Currency Exchange Gain (Loss)	-0.78	-0.55	0.76	2.47
EBT Excluding Unusual Items	-36.37	-34.55	-26.22	-11.87
Gain (Loss) on Sale of Investments	-	-	0.13	-
Other Unusual Items	-2.91	-9.07	-	-
Pretax Income	-39.28	-43.62	-26.09	-11.87
Net Income	-39.28	-43.62	-26.09	-11.87
Net Income to Common	-39.28	-43.62	-26.09	-11.87
Shares Outstanding (Basic)	24	6	6	6
Shares Outstanding (Diluted)	24	6	6	6
Shares Change (YoY)	292.49%	0.08%	0.00%	-
EPS (Basic)	-1.63	-7.08	-4.24	-1.93
EPS (Diluted)	-1.63	-7.08	-4.24	-1.93
Free Cash Flow	-22.62	-20.72	-20.66	-9.78
Free Cash Flow Per Share	-0.94	-3.36	-3.36	-1.59
Gross Margin	75.30%	2.45%	59.22%	62.67%
Operating Margin	-211.57%	-1213.93%	-914.76%	-380.89%
Profit Margin	-410.24%	-2018.28%	-1103.51%	-439.52%
Free Cash Flow Margin	-236.29%	-958.95%	-874.07%	-362.22%
EBITDA	-19.77	-25.6	-20.71	-9.61
D&A For EBITDA	0.48	0.64	0.92	0.67
EBIT	-20.26	-26.23	-21.63	-10.28
Revenue as Reported	2.16	2.16	2.36	2.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.